INT130371

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 1.59
Pain Relevance 0.45

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (PDE5A) signal transduction (PDE5A) cellular_component (PDE5A)
PDE5A (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 24 100.00 Very High Very High Very High
tolerance 8 85.36 High High
Pain 6 70.96 Quite High
headache 7 59.00 Quite High
nud 2 58.20 Quite High
Migraine 1 50.28 Quite High
Calcium channel 7 5.00 Very Low Very Low Very Low
cva 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 113 99.92 Very High Very High Very High
Increased Venous Pressure Under Development 12 94.28 High High
Pressure And Volume Under Development 5 90.88 High High
Reprotox - General 2 15 84.00 Quite High
Pain 7 70.96 Quite High
Headache 8 59.00 Quite High
Dyspepsia 2 58.20 Quite High
Dyspnea 9 47.20 Quite Low
Pressure Volume 2 Under Development 2 27.20 Quite Low
Disease 11 8.28 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In conclusion, PDE5 is present in human and guinea pig cerebral arteries, and is inhibited by sildenafil at micromolar levels.
Negative_regulation (inhibited) of Gene_expression (present) of PDE5
1) Confidence 0.43 Published 2005 Journal Eur. J. Pharmacol. Section Abstract Doc Link 16182282 Disease Relevance 0.19 Pain Relevance 0.10
Tadalafil, another PDE5 inhibitor approved for PAH earlier this year, is a once daily medication used at a dose of 40 mg daily.
Negative_regulation (inhibitor) of Gene_expression (approved) of PDE5 associated with pulmonary hypertension
2) Confidence 0.32 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2868348 Disease Relevance 0.66 Pain Relevance 0.04
Prostanoids, ERAs, and PDE5 inhibitors provide symptomatic relief and improve the functional as well as hemodynamic status of patients with PAH.
Negative_regulation (inhibitors) of Gene_expression (Prostanoids) of PDE5 associated with pulmonary hypertension and antagonist
3) Confidence 0.32 Published 2010 Journal Respir Res Section Body Doc Link PMC2835653 Disease Relevance 0.74 Pain Relevance 0.30

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox